NASDAQ · IINN
Inspira Technologies OXY B.H.N. Ltd.
$1.05-$0.01 (-0.94%)
Inspira Technologies OXY B.H.N. Ltd.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
Loading market information…
NASDAQ · AEMD · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Aethlon Medical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.6% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Aethlon Medical, Inc.’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of -$2.91. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Aethlon Medical, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:42 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Feb 12, 2025 |
| -$52.00+40.91% vs estimate |
| $0.00 |
| Q2 2025 | Nov 12, 2024 | -$80.00-7,900.0% vs estimate | $0.00 |
|---|
KEEP COMPARING
$1.05-$0.01 (-0.94%)
Inspira Technologies OXY B.H.N. Ltd.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$0.03-$0.00 (-9.41%)
Adaptimmune Therapeutics plc’s quoted price sits in the lower half of its reported 52-week range, 92.73% below the high.
$7.02+$0.28 (+4.08%)
enVVeno Medical Corporation’s quoted price sits in the lower half of its reported 52-week range, 73.37% below the high.
$2.11+$0.13 (+6.57%)
Ernexa Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.6% below the high.
$0.40-$0.05 (-10.49%)
Co-Diagnostics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.41% below the high.
$0.12-$0.00 (-1.07%)
Vivos Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.57% below the high.
$2.31-$0.05 (-2.12%)
Beyond Air, Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.66% below the high.
$2.29+$0.03 (+1.33%)
Tenon Medical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.97% below the high.
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $1.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
